Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Nurix Therapeutics Inc. is currently managing 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct art units, which indicates that the company's filings span several specialized technical groups within the patent office. The prosecution involves 6 distinct examiners, meaning that every pending action is currently being reviewed by a different individual. This high ratio of examiners to actions suggests a broad and decentralized prosecution landscape for the company.
CHEN, PO-CHIH is designated as the busiest examiner for the portfolio, currently holding 1 busiest examiner pending office action. Although CHEN, PO-CHIH is the busiest, the 1 busiest examiner pending action represents only a portion of the 6 pending office actions total. The fact that 6 distinct examiners are involved across 4 distinct art units suggests that the company must manage multiple distinct examiner styles. This distribution of 6 pending office actions requires a coordinated effort to maintain consistency across the Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| Double-patenting only | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, PO-CHIH | 1 | 74.2% | +14.8% |
| LEESER, ERICH A | 1 | 81.8% | +13.3% |
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
| GIERE, REBECCA M | 1 | 73.7% | +32.3% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18579114 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY | LEESER, ERICH A | 35d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17775265 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | HEITMEIER, KENDALL NICOLE | 39d |
| 18290920 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | CHEN, PO-CHIH | — |
| 18302603 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | GIERE, REBECCA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18579114 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY | LEESER, ERICH A | 35d |
| 17775265 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | HEITMEIER, KENDALL NICOLE | 39d |
| 18290920 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | CHEN, PO-CHIH | — |
| 18289513 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | HUI, SAN MING R | — |
| 18302603 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | GIERE, REBECCA M | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1622 | 1 |
| 1627 | 1 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18290920 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | CHEN, PO-CHIH | 1621 | §103§112Other | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18579114 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY | LEESER, ERICH A | 1622 | §103 | Final Rejection | 35d | Pending | Jan 12, 2024 |
| 18289513 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | HUI, SAN MING R | 1627 | DP | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18302603 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | GIERE, REBECCA M | 1677 | §101§112 | Non-Final OA | — | Pending | Jul 24, 2023 |
| 17775265 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | HEITMEIER, KENDALL NICOLE | 1621 | §103§112 | Non-Final OA | 39d | Pending | May 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial